Evidence map›Paper›PMID 32583342›Full record

ArticleJournal of general internal medicine2020

Perioperative Serum 25-Hydroxyvitamin D Levels as a Predictor of Postoperative Opioid Use and Opioid Use Disorder: a Cohort Study.

Yuhree Kim, Fang Zhang, Katherine Su, Marc LaRochelle, Matthew Callahan, David Fisher, J Frank Wharam, Maryam M Asgari

Open access · bronzeAbstract read
In one paragraph

Article in Journal of general internal medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. The Skin-Brain Axis: From UV and Pigmentation to Behaviour Modulation.International journal of molecular sciences · 2024
    Review
  7. Observational
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yuhree KimDepartment of Population Medicine, Harvard Medical School, , 401 Park Drive #401, Boston, MA, 02215, USA.
Fang ZhangDepartment of Population Medicine, Harvard Medical School, , 401 Park Drive #401, Boston, MA, 02215, USA.
Katherine SuDepartment of Population Medicine, Harvard Medical School, , 401 Park Drive #401, Boston, MA, 02215, USA.
Marc LaRochelleClinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center, , Boston, MA, USA.
Matthew CallahanDepartment of Population Medicine, Harvard Medical School, , 401 Park Drive #401, Boston, MA, 02215, USA.
David FisherDepartment of Dermatology, Massachusetts General Hospital, Harvard Medical School, , 50 Staniford Street, Boston, MA, USA.
J Frank WharamDepartment of Population Medicine, Harvard Medical School, , 401 Park Drive #401, Boston, MA, 02215, USA.
Maryam M AsgariDepartment of Population Medicine, Harvard Medical School, , 401 Park Drive #401, Boston, MA, 02215, USA. masgari@partners.org.ORCID 0000-0003-1582-3475
Harvard University · USBoston University · US

Funding

Transcriptional mechanisms and melanomaP01CA163222 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Kai W Wucherpfennig · 2013 to 2026
$25.3M
The MITF transcriptional network: melanoma risk and carcinogenesisR01AR043369 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI DAVID E FISHER · 1996 to 2026
$9.4M
Patient-oriented research and mentoring program in dermatologic diseasesK24AR069760 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI ASGARI, MARYAM MANDANA · 2017 to 2025
$1.9M
A druggable dependency in low-MITF/high-AXL melanoma: preclinical efficacy and mechanism of action in a key treatment-resistant subclass.R01CA222871 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FISHER, DAVID E · 2018 to 2022
$1.8M
NCI NIH HHS P01 CA163222NCI NIH HHS R01 CA222871NIAMS NIH HHS K24 AR069760NIAMS NIH HHS R01 AR043369NIH HHS K24 AR069760NIH HHS R01CA222871
6 · The paper itself

Abstract

importanceVitamin D deficiency is associated with chronic pain syndromes and higher opioid use among cancer patients, but its association with opioid use among opioid-naïve subjects following a major surgical procedure with acute pain has not been explored.

objectiveTo determine the association between serum 25-hydroxyvitamin D (25(OH)D) levels, opioid use, and opioid use disorder.

methodsWe identified commercially insured subjects aged 18-64 years with available perioperative serum 25-hydroxyvitamin D (25D) levels who underwent one of nine major surgical procedures in 2000-2014. Primary outcomes were dose and duration of opioid use measured using pharmacy claims. Secondary outcome was opioid use disorder captured using diagnosis codes. Multivariable negative binomial models with generalized estimating equations were performed examining the association between 25D levels and postoperative opioid use measures, adjusting for age, sex, race/ethnicity, Charlson score, education, income, latitude, and season of blood draw. Adjusted Cox regression was used to examine the association with opioid use disorder.

resultsAmong 5446 subjects, serum 25(OH)D was sufficient (≥ 20 ng/mL) among 4349 (79.9%) subjects, whereas 837 (15.4%) had insufficient (12 to < 20 ng/mL) and 260 (4.8%) had deficient (< 12 ng/mL) levels. On multivariable analysis, as compared with subjects with sufficient 25(OH)D levels, subjects with deficient 25(OH)D levels had 1.7 more days (95% CI 0.76, 2.58) of opioid use per year and had 98.7 higher morphine milligram equivalent dose (95% CI 55.7, 141.8) per year. Among 11,713 study cohort, subjects with deficient 25(OH)D levels were more likely to be diagnosed with opioid use disorders (HR 2.41; 95% CI 1.05, 5.52).

conclusionPatients undergoing common surgical procedures with deficient 25D levels are more likely to have higher opioid use and an increased risk of opioid use disorder compared to those with sufficient levels. Serum 25D levels may serve as a biomarker to identify subjects at increased risk of opioid misuse.

Indexed as

Analgesics, OpioidOpioid-Related DisordersAdolescentAdultCohort StudiesHumansMiddle AgedRisk FactorsVitamin DYoung Adult25-hydroxyvitamin DAnalgesics, OpioidVitamin D25(OH)Dchronic opioid useopioid-related disorders/epidemiologyopioid use disordervitamin D

Identifiers

PMID32583342
PMCPMC7459073
OpenAlexW3038104203

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.